Troutman Pepper advised Center for Breakthrough Medicines Holdings, LLC (CBM) in receiving $350 million in equity financing from an affiliate of SK Inc., the second largest conglomerate in South Korea. CBM is partnering with SK to create the world’s largest end-to-end cell and gene therapy contract development and manufacturing organization (CDMO). Read CBM’s press release about the partnership.

CBM offers fully integrated, bench to bedside, pre-clinical through commercial manufacturing capabilities including, process development, plasmid DNA, viral vector manufacturing, cell banking, cell processing, and a full suite of complimentary testing and analytic capabilities.

The Troutman Pepper team advising CBM in the financing was led by Rachael Bushey and Chris Miller, and included Saba Ashraf, Allison Nicklin, Stephen Fox, Roe Granger, Neil Doogan, Michael Crumbock, Susan Lessack, Joseph Harrington, Dan Scolnick, and Judy O’Grady.